Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adial Pharmaceuticals Inc (ADIL)
NASDAQ:ADIL
RESEARCH TOOLSreports
Holding ADIL?
Track your performance easily
ADIL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.77 - $4.17
Previous Close$1.02
Volume16.38K
Average Volume (3M)145.61K
Market Cap
$6.41M
Enterprise Value$1.33M
Total Cash (Recent Filing)$5.20M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Mar 27, 2025EPS Estimate
-$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.31
Shares Outstanding6,405,781
10 Day Avg. Volume320,348
30 Day Avg. Volume145,614
Standard Deviation0.32
R-Squared0.04
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.11
Price to Sales (P/S)14.38
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.95
Enterprise Value/Gross Profit2.95
Enterprise Value/Ebitda-0.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Adial Pharmaceuticals News
PremiumCompany Announcements
Adial Pharmaceuticals Advances AD04 with Promising Study Results
PremiumCompany Announcements
Adial Pharmaceuticals Approves Strategic Changes at Annual Meeting
PremiumCompany Announcements
Adial Pharmaceuticals Appoints New Chief Financial Officer
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentAdial announced positive top-line results from its pharmacokinetics (PK) study of AD04, which confirmed the relative bioavailability to marketed ondansetron and no food effects.
Leadership And ExperienceNew leadership appointment with Vinay Shah as the company's CFO brings over 25 years of experience in the pharmaceutical, biopharmaceutical, and healthcare sectors, specializing in financial strategy.
Regulatory ApprovalAdial announced positive feedback from US and EU regulators around its AD04 program, following regulatory meetings.
Bears Say
Cash PositionThe company's cash reserves stand at $5.2 million, raising concerns about its ability to sustain operations without additional funding.
Financial PerformanceAdial reported a net loss of $2.2 million, indicating financial struggles.
Financing OverhangAdditional capital is required to advance the company's program, highlighting the ongoing financial overhang and uncertainty about future funding.
---
Ownership Overview
35.10%
Insiders
0.54% Mutual Funds
0.81% Other Institutional Investors
63.41% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ADIL FAQ
What was Adial Pharmaceuticals Inc’s price range in the past 12 months?
Adial Pharmaceuticals Inc lowest stock price was $0.77 and its highest was $4.17 in the past 12 months.
What is Adial Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Adial Pharmaceuticals Inc’s upcoming earnings report date?
Adial Pharmaceuticals Inc’s upcoming earnings report date is Mar 27, 2025 which is in 124 days.
How were Adial Pharmaceuticals Inc’s earnings last quarter?
Adial Pharmaceuticals Inc released its earnings results on Nov 13, 2024. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.4 by $0.02.
Is Adial Pharmaceuticals Inc overvalued?
According to Wall Street analysts Adial Pharmaceuticals Inc’s price is currently Overvalued.
Does Adial Pharmaceuticals Inc pay dividends?
Adial Pharmaceuticals Inc does not currently pay dividends.
What is Adial Pharmaceuticals Inc’s EPS estimate?
Adial Pharmaceuticals Inc’s EPS estimate is -$0.31.
How many shares outstanding does Adial Pharmaceuticals Inc have?
Adial Pharmaceuticals Inc has 6,405,781 shares outstanding.
What happened to Adial Pharmaceuticals Inc’s price movement after its last earnings report?
Adial Pharmaceuticals Inc reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.4. Following the earnings report the stock price went down -2.941%.
Which hedge fund is a major shareholder of Adial Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ADIL
---
Adial Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
ADIL Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Negative
Last 7 Days ▲ 1.6%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.21%
12-Months-Change
Fundamentals
Return on Equity
-316.95%
Trailing 12-Months
Asset Growth
134.10%
Trailing 12-Months
Company Description
Adial Pharmaceuticals Inc
Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which is focused on the treatment of alcohol use disorder. Its lead product AD04, a selective serotonin-3 antagonist is in Phase 3 clinical trial. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.
---
ADIL Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering ADIL
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-49.30%
reiterated a buy rating 9 months ago
Copying Kemp Dolliver's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -49.30% per trade.
---